Keeping up-to-date with the latest advances in IBD can be challenging. That’s why each month we will be selecting some of the most important recent peer-reviewed publications on the management of Crohn’s disease and ulcerative colitis to highlight.
Key insights and core messages will be distilled into a publication infographic that aims to provide an accessible and memorable overview of each publication. Take a look at the infographics available below and don’t forget to come back regularly to discover the latest publications that have been covered.
This study investigates the diagnostic performance of PET/MR and demonstrates that new non-invasive radiological techniques, which enable accurate detection of active inflammation, may play an increasingly important role in the management of Crohn’s disease.
The inflammatory nature of ulcerative colitis (UC) has long been associated with the development of colorectal neoplasia (CRN). Current guidelines published by the British Society of Gastroenterology recommend assessing an individual’s risk of developing CRN based on the severity of inflammation seen at the most recent colonoscopy.
The use of biosimilars in patients with inflammatory bowel disease (IBD) remains a topic of debate. While they offer a cheaper alternative to the originator version, does switching treatments have an effect on patient outcomes? In this study, Binkhorst et al. explore how switching to a biosimilar version of infliximab affects IBD disease activity.
The incidence of inflammatory bowel disease (IBD) varies around the world, but what is the reason behind the ever-changing incidence? In this study, Marín-Jiménez et al. explore the incidence and resource use of IBD patients in Spain for a closer look at how local rates compare to European trends.
Many patients with IBD have their condition controlled with anti-TNF treatment, but what happens should they not respond? In this retrospective, observational study, Buhl and colleagues explore the outcomes of patients with ulcerative colitis or Crohn’s disease who do not respond to first-line anti-TNF therapy.
Patients with active Crohn’s disease should have their treatment escalated, but how should that decision be made? In this open-label, randomised, controlled Phase 3 study, Colombel et al., explore whether the addition of biomarkers of intestinal inflammation to a treatment decision algorithm helps improve endoscopic and clinical outcomes in patients with moderate-to-severe Crohn’s disease.
Alternatively login via
Back to epgonline.org